Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

doi:10.1158/1078-0432.CCR-15-2245

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2016

Zumsteg Zachary S, Morse Natasha, Krigsfeld Gabriel, Gupta Gaorav, Higginson Daniel S, Lee Nancy Y, Morris Luc, Ganly Ian, Shiao Stephan L, Powell Simon N, Chung Christine H, Scaltriti Maurizio, Baselga José

Abstract excerpt

PURPOSE: ActivatingPIK3CAgenomic alterations are frequent in head and neck squamous cell carcinoma (HNSCC), and there is an association between phosphoinositide 3-kinase (PI3K) signaling and radioresistance. Hence, we investigated the therapeutic efficacy of inhibiting PI3K with GDC-0032, a PI3K inhibitor with potent activity against p110α, in combination with radiation in HNSCC. EXPERIMENTAL DESIGN: The efficacy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Breaks, Double-Stranded

Share to G2 Phase Cell Cycle Checkpoints

Share to Head and Neck Neoplasms

Share to Imidazoles

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Radiation-Sensitizing Agents

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed Open full text

Identifiers

PMID: 26589432
DOI: 10.1158/1078-0432.CCR-15-2245
PMCID: PMC4870591

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.PMID 26589432Read ↗

The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cellsSemantic proximity Read ↗

Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)Semantic proximity Read ↗

Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell CarcinomasSemantic proximity Read ↗

IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck CancerSemantic proximity Read ↗

Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH TrialSemantic proximity Read ↗

The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.Semantic proximity Read ↗

Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targetingSemantic proximity Read ↗

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.Semantic proximity Read ↗

Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.Semantic proximity Read ↗

Impact of PI3K pathway alterations on response to immune checkpoint inhibitors in HPV-negative head and neck squamous cell carcinomaSemantic proximity Read ↗

Molecular pathways in head and neck cancer: EGFR, PI3K, and more.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.